VOL. XCIV, NO. 247
WIDE MOAT STOCKS COMPARISON
Stock Comparison
Luzhou Laojiao Co., Ltd. vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Luzhou Laojiao Co., Ltd.
000568.SZ · Shenzhen Stock Exchange
Weighted across the company's segments.
Full stock profile
Dive deeper into Luzhou Laojiao Co., Ltd.'s moat claims, evidence, and risks.
View 000568.SZ analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted across the company's segments.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: Luzhou Laojiao Co., Ltd. leads (73 / 100 vs 64 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Luzhou Laojiao Co., Ltd. has 3 segments (87.9% in Mid- and high-end baijiu); Bristol-Myers Squibb Company has 5 segments (34.5% in Eliquis franchise (apixaban)).
- Moat breadth: Luzhou Laojiao Co., Ltd. has 2 moat types across 2 domains; Bristol-Myers Squibb Company has 2 across 2.
Primary market context
Luzhou Laojiao Co., Ltd.
Mid- and high-end baijiu
Mid- and high-priced baijiu in China, centered on strong-aroma products priced at least CNY150 per bottle
China (primarily); limited exports
Consumers buying for personal consumption, gifting, and banquets through distributors, retail, and e-commerce
Distiller, owner of National Cellar 1573 and Luzhou Laojiao brands, and supplier to authorized distributors
87.9%
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
34.5%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Luzhou Laojiao Co., Ltd. strengths
Bristol-Myers Squibb Company strengths
Segment mix
Luzhou Laojiao Co., Ltd. segments
Full profile >Mid- and high-end baijiu
Oligopoly
Other baijiu (mainstream/value)
Competitive
Other revenues
Competitive
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Act on this comparison
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.